Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by BearDownAZon May 30, 2013 1:07pm

169 Views

Post# 21461631

RE: RE: RE: RE: RE: RE: RE: RE: RE: bghg, you ar

Read the arrangment. It clearly states that the 6-12% royalty is paid to Newco, not Newco shareholders. That is what I mean by no obligation. As for fouremm's comment about the remaining 88-94% of royalty coming to RVX shareholdes, I think this is "fuzzy math." Assuming that BP buys RVX, we will no longer hold RVX shares. They will have been purchased from us. Therefore whatever BP buys RVX will get the 88-94% of remaining royalties.

Bullboard Posts

Paramount Resources signs $3.32 billion asset sale